Alterity's Parkinson's Candidate Prevents Loss Of Brain Cells In Animal Model

Vandana Singh
1 min read
0
In this article:

  • Alterity Therapeutics (NASDAQ: ATHE) announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson's disease (PD).

  • The publication assessed the impact of ATH434 on motor and non-motor deficits in mice with genetically induced Parkinson's disease.

  • Hyposmia, defined as reduced sensitivity to odor, is an early and common non-motor symptom of PD that precedes the typical motor symptoms by several years, occurring in approximately 90% of early-stage cases of PD2.

  • The study found that ATH434 prevented a loss of smell in the younger mice and rescued it in older mice.

  • The authors also demonstrated that ATH434 prevented the development of motor impairment in older animals, which was associated with a reduction in iron levels and preservation of neurons in the substantia nigra, the brain region affected in Parkinson's.

  • These data support other studies indicating that ATH434 has a beneficial effect on motor and non-motor symptoms in animal models of PD.

  • Price Action: ATHE shares are up 8.95% at $4.26 on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article originally appeared on Benzinga.com

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement

Recommended Stories